Recent Updates
Recently added Catalysts
BNGO Positive Sentiment Score: 75/100

Bionano to Present at the Canaccord Genuity 43rd Annual Growth Conference

Key Takeaway: Bionano Genomics, Inc. announced that its CEO, Erik Holmlin, will present at the Canaccord Genuity 43rd Annual Growth Conference on August 10, 2023. The conference aims to connect institutional investors with promising growth companies. Bionano specializes in genome analysis solutions and offers diagnostic services and software to support researchers and clinicians. This presentation is expected to elevate the company's visibility in the biotechnology sector.

Market Sentiment Analysis

POSITIVE FACTORS

  • Bionano is participating in a prominent growth conference, signaling confidence and visibility.
  • The presentation will feature Bionano's CEO, enhancing credibility and interest.
  • The company provides advanced genome analysis solutions, which could attract investor interest.

Full Press Release Details

SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, Ph.D., Bionano’s president and chief executive officer will present at the Canaccord Genuity 43rd Annual Growth Conference on August 10, 2023.
Conference & Webcast Details
Date: Thursday, August 10th, 2023
Time: 11:30 a.m. to 11:55 a.m. ET
Presenter: Erik Holmlin, Ph.D., CEO of Bionano
Webcast: https://wsw.com/webcast/canaccord89/bngo/2447258
A replay / recording of the session will be available following the conference through the Bionano website at https://ir.bionano.com/ for at least 30 days.
About the Canaccord Genuity 43rd Annual Growth Conference
This annual event brings together institutional investors from across the globe with some of the best and most promising growth companies in Canaccord Genuity’s core sectors - Technology, Healthcare & Life Sciences, Sustainability, Industrials, and Consumer & Retail.
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. The Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. For more information, visit www.bionano.com, www.bionanolaboratories.com or www.purigenbio.com.
Bionano Genomics, Inc.

Frequently Asked Questions

When will Bionano present at the Canaccord Genuity conference?

Bionano will present on August 10, 2023, from 11:30 a.m. to 11:55 a.m. ET.

Who is presenting for Bionano at the conference?

Erik Holmlin, Ph.D., Bionano’s CEO, will be the presenter.

How can I access the webcast of the presentation?

The webcast can be accessed at https://wsw.com/webcast/canaccord89/bngo/2447258.

Will there be a replay of the presentation available?

Yes, a replay will be available on Bionano's website for at least 30 days.

What does Bionano Genomics focus on?

Bionano specializes in genome analysis solutions for research and diagnostics.

Last updated: Jul 27, 2023